ArticleHealth science reports2026
Hematologic Toxicities and Determinants Among Patients With Breast Cancer Treated With Doxorubicin-Cyclophosphamide Followed by Paclitaxel in Northwest Ethiopia: A Retrospective Cohort Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Hematologic toxicities are common during breast cancer chemotherapy, but data from Ethiopia are limited. This study assessed hematologic toxicities and associated factors among patients treated with doxorubicin-cyclophosphamide followed by paclitaxel (ACT) regimen in Northwest Ethiopia. Methods: A retrospective cohort study was conducted among 422 patients with breast cancer treated with the AC-T regimen from January 2019 to August 2023 in Northwest Ethiopia. Data were collected from July to August 2023. Factors associated with hematologic toxicities were identified using binary logistic regression, with adjusted odds ratio (AOR), 95% confidence interval (CI), and a two-sided Results: Among 422 patients, the prevalence of chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced thrombocytopenia (CIT), and neutropenic fever (NF) was 61.8%, 44.1%, 16.4%, and 10.0%, respectively. Older age (≥ 43 years) (AOR = 3.5, 95% CI: 2.2-5.7, Conclusions: Hematologic toxicities were common with the ACT regimen and associated with older age, rural residence, advanced stage, comorbidities, and lobular/mixed histology, warranting close monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.